Overview

Phase 3 Study of ALK-001 in Geographic Atrophy

Status:
Active, not recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Alkeus Pharmaceuticals, Inc.

Treatments:

Retinol acetate
Vitamin A